CONTACT: Alan Robertson - Chief Executive OfficerPh: +61 2 9454 7200 or email alan.robertson@pharmaxis.com.auRELEASED THROUGH:Australia:

SYDNEY, Australia, May 4 /PRNewswire-Asia-FirstCall/ -- Pharmaceutical company Pharmaxis (ASX: PXS; Nasdaq: PXSL) is pleased to announce positive results of its recently completed international Phase III trial of Bronchitol(TM) in people with cystic fibrosis.

SYDNEY, Australia, Sept. 4 /Xinhua-PRNewswire-FirstCall/ -- Pharmaceutical company Pharmaxis today announced that it has enrolled the first subject into its second pivotal Phase 3 clinical trial evaluating Bronchitol in cystic fibrosis sufferers.

SYDNEY, Australia, Aug.

SYDNEY, Australia, Aug. 17 /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis today announced that the first pivotal Phase 3 clinical trial of Bronchitol for the treatment of cystic fibrosis has completed enrolment.